Koninklijke Philips (PHG) to Release Earnings on Tuesday

Koninklijke Philips (NYSE:PHG - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect Koninklijke Philips to post earnings of $0.29 per share and revenue of $4.35 billion for the quarter.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its earnings results on Tuesday, May 6th. The technology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.13. The firm had revenue of $4.31 billion during the quarter, compared to analyst estimates of $4.10 billion. Koninklijke Philips had a return on equity of 10.97% and a net margin of 2.11%. The business's revenue was down 1.0% compared to the same quarter last year. During the same period last year, the firm posted $0.21 EPS. On average, analysts expect Koninklijke Philips to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Koninklijke Philips Stock Performance

Shares of NYSE PHG traded down $0.03 during mid-day trading on Thursday, reaching $25.83. 1,008,659 shares of the company's stock were exchanged, compared to its average volume of 968,875. The firm has a 50-day moving average price of $23.63 and a two-hundred day moving average price of $24.93. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.28 and a quick ratio of 0.79. The firm has a market capitalization of $24.87 billion, a price-to-earnings ratio of 60.08, a price-to-earnings-growth ratio of 0.70 and a beta of 0.76. Koninklijke Philips has a 52 week low of $21.48 and a 52 week high of $32.91.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Koninklijke Philips from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy".

Institutional Trading of Koninklijke Philips

Large investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its position in shares of Koninklijke Philips by 1.3% during the 1st quarter. Royal Bank of Canada now owns 269,829 shares of the technology company's stock valued at $6,854,000 after buying an additional 3,540 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Koninklijke Philips by 60.8% during the first quarter. AQR Capital Management LLC now owns 17,010 shares of the technology company's stock valued at $432,000 after purchasing an additional 6,429 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Koninklijke Philips by 1.5% during the first quarter. Goldman Sachs Group Inc. now owns 846,253 shares of the technology company's stock worth $21,495,000 after purchasing an additional 12,908 shares during the period. Finally, Jane Street Group LLC lifted its stake in shares of Koninklijke Philips by 125.8% during the 1st quarter. Jane Street Group LLC now owns 104,024 shares of the technology company's stock valued at $2,642,000 after buying an additional 57,952 shares in the last quarter. 13.67% of the stock is owned by hedge funds and other institutional investors.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.